Your browser is no longer supported. Please, upgrade your browser.
MRTX Mirati Therapeutics, Inc. weekly Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.83 Insider Own0.40% Shs Outstand38.07M Perf Week0.04%
Market Cap4.02B Forward P/E- EPS next Y-5.50 Insider Trans-91.51% Shs Float37.58M Perf Month9.98%
Income-124.60M PEG- EPS next Q-1.21 Inst Own- Short Float14.31% Perf Quarter59.85%
Sales4.70M P/S854.96 EPS this Y-14.40% Inst Trans10.24% Short Ratio7.03 Perf Half Y73.43%
Book/sh8.11 P/B13.01 EPS next Y-11.30% ROA-47.40% Target Price110.42 Perf Year116.74%
Cash/sh7.91 P/C13.35 EPS next 5Y- ROE-52.10% 52W Range28.50 - 109.64 Perf YTD148.82%
Dividend- P/FCF- EPS past 5Y7.80% ROI- 52W High-3.73% Beta1.99
Dividend %- Quick Ratio12.20 Sales past 5Y- Gross Margin- 52W Low270.35% ATR3.92
Employees63 Current Ratio12.20 Sales Q/Q-87.40% Oper. Margin- RSI (14)63.10 Volatility2.64% 3.78%
OptionableYes Debt/Eq0.00 EPS Q/Q-129.30% Profit Margin- Rel Volume0.34 Prev Close105.71
ShortableYes LT Debt/Eq0.00 EarningsJul 31 BMO Payout- Avg Volume764.90K Price105.55
Recom2.10 SMA202.10% SMA5020.03% SMA20065.92% Volume256,404 Change-0.15%
Jun-19-19Downgrade B. Riley FBR Buy → Neutral $60 → $92
Jun-07-19Downgrade Guggenheim Buy → Neutral
Jun-05-19Reiterated H.C. Wainwright Buy $84 → $117
Jun-04-19Upgrade Citigroup Neutral → Buy $76 → $132
Apr-17-19Initiated JP Morgan Neutral $72
Mar-25-19Initiated Credit Suisse Outperform $85
Mar-04-19Downgrade Citigroup Buy → Neutral $64 → $77
Feb-15-19Initiated Piper Jaffray Overweight $85
Dec-03-18Initiated B. Riley FBR Buy $60
Oct-29-18Upgrade Guggenheim Neutral → Buy
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Mar-12-18Initiated Barclays Overweight $44
Jan-09-18Reiterated H.C. Wainwright Buy $17 → $21
Nov-14-17Upgrade Leerink Partners Mkt Perform → Outperform
Oct-12-17Resumed H.C. Wainwright Buy $20
Sep-19-17Initiated Oppenheimer Outperform $18
Sep-15-17Reiterated Leerink Partners Mkt Perform $7 → $9
Nov-17-16Initiated H.C. Wainwright Buy $12
Jun-06-16Reiterated Wedbush Outperform $29 → $27
Jun-06-16Downgrade Leerink Partners Outperform → Mkt Perform
Jul-10-19 05:53PM  Mirati Inks Deal with Novartis to Evaluate Tumor Candidate Zacks
04:41PM  How This Novartis Mashup Could Validate A Biotech Company's Cancer Drug Investor's Business Daily
07:17AM  The Daily Biotech Pulse: Jazz Buys Tumor Drug Program, Sanofi's BLA For Multiple Myeloma Drug Accepted, Positive Results For ViiV Benzinga
Jul-09-19 04:30PM  Mirati Announces Clinical Collaboration to Evaluate MRTX849 in Combination with SHP2 Inhibitor TNO155 PR Newswire
Jul-02-19 07:29AM  The Daily Biotech Pulse: Celyad To Advance Leukemia Drug To Clinical Trial, Positive Data For Teva's Migraine Drug Benzinga
Jul-01-19 04:30PM  Mirati Therapeutics Announces The Appointment Of Dr. Julie Cherrington To The Board Of Directors PR Newswire
Jun-30-19 08:00AM  3 Top Biotech Stocks to Buy Right Now Motley Fool
Jun-27-19 04:05PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jun-25-19 08:30AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-24-19 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
09:43AM  Read This Before You Buy Any New Cancer Drug Stocks Motley Fool
Jun-18-19 07:09AM  Shares of cancer-therapy companies skyrocket after Pfizer acquisition news MarketWatch
Jun-14-19 08:41AM  Implied Volatility Surging for Mirati Therapeutics (MRTX) Stock Options Zacks
Jun-13-19 11:51AM  3 Under-the-Radar Stocks Trading at All-Time Highs Investopedia
Jun-12-19 10:03AM  Mirati Therapeutics, Inc. (NASDAQ:MRTX): Financial Strength Analysis Simply Wall St.
Jun-10-19 10:26AM  Hedge Funds Have Never Been This Bullish On Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Jun-06-19 03:12PM  Mirati Therapeutics Could Soar Even Higher TheStreet.com
Jun-05-19 07:30AM  The Daily Biotech Pulse: Curtains Down On ASCO, Rewalk Flies, Eli Lilly's Migraine Drug Approved For Cluster Headache Benzinga
Jun-04-19 03:18PM  The 10 Best Stocks for 2019 So Far InvestorPlace +9.90%
12:37PM  Amgens Good News on Lung Cancer Boosted Mirati Therapeutics. Heres What Wall Street Is Saying. Barrons.com
10:53AM  How Does Mirati's Lung Cancer Candidate Stack Up Against Amgen's? Benzinga
10:19AM  Amgen's KRAS Inhibitor Shows Impressive Anti-Tumor Activity Zacks
09:21AM  3 Cancer Stocks Given a Lift by Amgen Motley Fool
Jun-03-19 02:46PM  Why Cancer-Fighting Stocks & ETFs Are Soaring Zacks +31.58%
12:47PM  Amgen Stock Jumps on Promising Cancer Drug Trial Results Barrons.com
12:18PM  Here's Why Mirati Therapeutics Is Jumping Today Motley Fool
May-31-19 01:04PM  What to watch at the world's largest cancer conference CNBC Videos
May-30-19 04:30PM  Mirati Therapeutics To Present At Jefferies 2019 Global Healthcare Conference PR Newswire
May-16-19 04:14PM  Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting Investor's Business Daily +11.13%
02:47PM  Here's Why Mirati Therapeutics Is Surging Today Motley Fool
10:47AM  What's Triggering The Rise In Mirati Shares? Benzinga
May-14-19 08:42AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
May-07-19 07:10AM  What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value Simply Wall St.
Apr-29-19 05:10PM  Mirati: 1Q Earnings Snapshot Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2019 Financial Results PR Newswire
02:52PM  Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ? Insider Monkey
Apr-01-19 04:30PM  Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference PR Newswire
Mar-26-19 12:21PM  The Mirati Therapeutics (NASDAQ:MRTX) Share Price Has Gained 287%, So Why Not Pay It Some Attention? Simply Wall St.
Mar-05-19 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-28-19 04:15PM  Mirati Therapeutics Reports Fourth Quarter Financial Results PR Newswire -5.02%
Feb-25-19 08:10AM  Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-19-19 04:15PM  Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors PR Newswire
Feb-07-19 04:30PM  Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day PR Newswire
Feb-04-19 05:01PM  Here's Why Mirati Therapeutics Jumped 55.8% in January Motley Fool
Jan-31-19 07:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics ACCESSWIRE
Jan-30-19 11:41AM  How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares? Simply Wall St. +5.31%
Jan-23-19 07:22AM  The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study Benzinga
Jan-22-19 04:01PM  Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares PR Newswire
Jan-17-19 08:06AM  The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US Benzinga
Jan-16-19 08:45PM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
04:01PM  Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire
Jan-15-19 04:21PM  Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor PR Newswire
07:55AM  Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics ACCESSWIRE
Jan-10-19 06:00AM  Kill the Cancer Stem Cell, Kill the Cancer: How One Biotech is Hitting Cancer at the Cause ACCESSWIRE +13.27%
Jan-09-19 08:39AM  Mirati Therapeutics (MRTX) Catches Eye: Stock Jumps 5.4% Zacks +5.46%
Jan-07-19 08:30AM  Mirati Announces Clinical Collaboration With Bristol-Myers Squibb For The Planned Phase 3 Trial In Non-Small Cell Lung Cancer To Evaluate Sitravatinib In Combination With Nivolumab (OPDIVO®) PR Newswire +7.31%
Jan-02-19 04:30PM  Mirati Therapeutics To Present At The 37th Annual J.P. Morgan Healthcare Conference PR Newswire +5.26%
Dec-20-18 04:42PM  Mirati Therapeutics Added To NASDAQ Biotechnology Index PR Newswire
Dec-12-18 03:27AM  Hedge Funds Are Buying Mirati Therapeutics, Inc. (MRTX) Insider Monkey
Dec-10-18 04:15PM  Mirati Therapeutics Announces The Appointment Of Maya Martinez-Davis To The Board Of Directors PR Newswire
Dec-04-18 07:20AM  Investor Expectations to Drive Momentum within Mirati Therapeutics, comScore, Nuance Communications, Carnival, Aerie Pharmaceuticals, and TrueCar Discovering Underlying Factors of Influence GlobeNewswire
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-29-18 05:20PM  Mirati Therapeutics Announces FDA Clearance Of Investigational New Drug (IND) Application To Initiate Phase 1/2 Trial Of KRAS G12C Inhibitor, MRTX849 PR Newswire -5.56%
Nov-20-18 04:30PM  Mirati Therapeutics To Present At The 30th Annual Piper Jaffray Healthcare Conference PR Newswire
Nov-09-18 08:35AM  Mirati Presents Preliminary Biomarker Data From Ongoing Phase 2 Clinical Trial Of Sitravatinib In Combination With Nivolumab At The SITC 33rd Annual Meeting PR Newswire -5.65%
08:30AM  Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting PR Newswire
Nov-08-18 04:32PM  Mirati Therapeutics Announces First Patient Dosed In Phase 1b Clinical Trial Of Sitravatinib In Combination With Anti-PD1 Antibody Tislelizumab In Patients With Advanced Solid Tumors PR Newswire
Nov-07-18 09:00AM  Mirati Therapeutics To Present At The 27th Annual Credit Suisse Healthcare Conference PR Newswire +6.95%
Nov-06-18 06:52PM  Mirati: 3Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Third Quarter Financial Results PR Newswire
Nov-05-18 04:15PM  Mirati To Present New Data In Ongoing Phase 2 Clinical Trials At The SITC 33rd Annual Meeting PR Newswire
Oct-30-18 09:00AM  Mirati Therapeutics Announces Submission of IND Application for MRTX849, a KRAS G12C Inhibitor, to Treat Non-Small Cell Lung Cancer and Colorectal Cancer PR Newswire +6.11%
Oct-25-18 08:50AM  Research Report Identifies CSG Systems International, Zumiez, Urban Outfitters, Mirati Therapeutics, Applied Materials, and Xencor with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire +5.50%
Oct-22-18 04:49PM  Mirati Shares Fall After Cancer Trial Progress Report TheStreet.com -15.00%
04:45PM  Biotech Dives After Lung Cancer Regimen With Bristol Disappoints Investor's Business Daily
04:26PM  These Companies Are Dragging Biotech Stocks Into A Pit On Cancer Tests Investor's Business Daily
11:51AM  Why Mirati Therapeutics Inc. Is Plunging Today Motley Fool
10:37AM  Mirati Therapeutics stock drops 19.5% after cancer trial results MarketWatch
06:10AM  Mirati Therapeutics Presents Updated Positive Clinical Data From Sitravatinib Immuno-Oncology Combination Trial At ESMO 2018 Congress And Announces FDA Guidance For Registration Trial PR Newswire
Oct-21-18 05:10AM  Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress PR Newswire
Oct-15-18 04:30PM  Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call PR Newswire
Oct-09-18 09:41AM  3 Biotech Stocks With Major Incoming Catalysts Motley Fool
Oct-08-18 05:29PM  Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy Zacks
Sep-14-18 11:15AM  Mirati Therapeutics Inc (NASDAQ:MRTX): Time For A Financial Health Check Simply Wall St.
Aug-29-18 04:30PM  Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference PR Newswire
Aug-24-18 07:11AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Aug-16-18 04:30PM  Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition PR Newswire
Aug-01-18 06:53PM  Mirati: 2Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Second Quarter Financial Results PR Newswire
09:15AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Jul-28-18 08:00AM  How to Invest in Clinical-Stage Biotechs Without Losing Money Motley Fool
Jul-24-18 04:59PM  Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress PR Newswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE +5.11%
Jun-25-18 04:30PM  Mirati Therapeutics Added to Russell 2000® Index PR Newswire
Jun-15-18 09:20AM  Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar? Zacks
Jun-11-18 04:15PM  Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-07-18 11:26AM  Here's Why Mirati Therapeutics, Inc. Is Rising Today Motley Fool +18.40%
08:00AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-06-18 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
May-31-18 04:30PM  Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting PR Newswire
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company is involved in developing sitravatinib, a spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of non-small cell lung cancer (NCSLC); and in Phase Ib clinical trial to treat NCSLC patients with Casitas B-lineage Lymphoma genetic alterations, as well as KRAS G12C inhibitor program for NSCLC adenocarcinoma patients, colorectal cancer patients, and other cancers. It also develops mocetinostat, an orally investigational selective Class I and IV histone deacetylase inhibitor that has completed Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. The company has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a Clinical Collaboration Agreement with Novartis International AG. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CARTER BRUCE L ADirectorMay 22Option Exercise6.783,00020,3403,000May 24 05:00 PM
CARTER BRUCE L ADirectorMay 22Sale75.203,000225,5970May 24 05:00 PM
Donadio Jamie ASr. VP, CFOMay 16Option Exercise5.507,50041,2507,721May 20 07:00 PM
Donadio Jamie ASr. VP, CFOMay 16Sale75.007,500562,500221May 20 07:00 PM
GREY MICHAEL GDirectorMay 13Option Exercise16.847,100119,5647,100May 15 07:00 PM
GREY MICHAEL GDirectorMay 13Sale65.305,760376,1381,340May 15 07:00 PM
venBio Select Advisor LLC10% OwnerMar 20Sale72.8023,7811,731,2573,862,500Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 19Sale73.43100,0007,343,0003,886,281Mar 20 04:05 PM
venBio Select Advisor LLC10% OwnerMar 18Sale76.55125,0009,568,7503,986,281Mar 20 04:05 PM
Boxer Capital, LLC10% OwnerMar 01Option Exercise0.00425,0064251,715,566Mar 05 09:30 PM
Braslyn Ltd.10% OwnerMar 01Option Exercise0.00275,0042753,135,970Mar 05 09:30 PM
Boxer Capital, LLC10% OwnerMar 01Sale69.00425,00029,325,0001,290,560Mar 05 09:30 PM
Braslyn Ltd.10% OwnerMar 01Sale69.00275,00018,975,0002,860,966Mar 05 09:30 PM
BAUM CHARLES MPresident & CEOFeb 25Option Exercise8.5051,810440,385117,851Feb 27 07:00 PM
BAUM CHARLES MPresident & CEOFeb 25Sale75.6751,8103,920,67266,041Feb 27 07:00 PM
BAUM CHARLES MPresident & CEOFeb 21Option Exercise21.583,62378,17366,041Feb 25 08:04 PM
CARTER BRUCE L ADirectorFeb 20Option Exercise6.783,00020,3403,000Feb 22 07:00 PM
venBio Select Advisor LLC10% OwnerFeb 20Sale73.00686,82050,137,8604,111,281Feb 21 04:10 PM
CARTER BRUCE L ADirectorFeb 20Sale73.643,000220,9210Feb 22 07:00 PM
Donadio Jamie ASr. VP, CFOFeb 15Option Exercise5.407,50040,5007,721Feb 19 07:00 PM
Donadio Jamie ASr. VP, CFOFeb 15Sale75.007,500562,502221Feb 19 07:00 PM
LEMASTERS CHRISTOPHER C.EVP, Chief Business OfficerFeb 14Option Exercise6.4560,000387,00060,000Feb 19 07:00 PM
LEMASTERS CHRISTOPHER C.EVP, Chief Business OfficerFeb 14Sale71.7760,0004,306,4550Feb 19 07:00 PM
Johnson Craig ADirectorJan 29Option Exercise8.6517,000147,03017,000Jan 31 07:00 PM
Johnson Craig ADirectorJan 29Sale61.4617,0001,044,7730Jan 31 07:00 PM
CHEN ISANEVP, Chief Medical OfficerJan 23Option Exercise22.4787019,54735,836Jan 25 07:00 PM
Boxer Capital, LLC10% OwnerJan 17Buy62.00150,0009,300,0001,715,560Jan 22 05:34 PM
Reisman Neil10% OwnerJan 11Option Exercise12.8925,972334,68739,103Jan 15 09:15 PM
Boxer Capital, LLC10% OwnerJan 09Option Exercise0.00150,0031501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 09Sale51.55150,0007,732,1001,415,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Option Exercise0.00550,0125501,565,560Jan 09 09:31 PM
Boxer Capital, LLC10% OwnerJan 08Sale52.10550,00028,657,0721,015,560Jan 09 09:31 PM
Davis Aaron I.DirectorJan 08Sale52.8010,000528,00037,052Jan 09 09:31 PM
Davis Aaron I.DirectorJan 07Sale46.4040,0001,855,80347,052Jan 09 09:31 PM
Christensen JamieEVP, Chief Scientific OfficerDec 26Option Exercise17.415,16989,9928,789Dec 28 07:00 PM
BAUM CHARLES MPresident & CEOAug 24Option Exercise17.4111,486199,97162,418Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Option Exercise8.5051,810440,385102,742Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Sale57.5551,8102,981,78850,932Aug 24 07:00 PM